SEC Form 4 · accession 0000899243-17-012356
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth Czerepak
Officer — See Remarks
Period of report
May 4, 2017
Accepted (ET)
May 8, 2017 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (option to buy)F2,F1 | $13.35 | May 4, 2017 | A | 178,595 | A | — | May 27, 2025 | Common Stock, par value $0.0001 | 178,595 | 178,595 | D |
| Stock Option (option to buy)F2,F3 | $13.38 | May 4, 2017 | A | 18,727 | A | — | Apr 7, 2016 | Common Stock, par value $0.0001 | 18,727 | 18,727 | D |
Explanation of responses
- F1The option is currently exercisable to purchase 119,207 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The option to purchase the remaining 59,388 shares of Common Stock will vest in equal installments on a monthly basis until 4/7/2019.
- F2Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
- F3The option is currently exercisable to purchase 6,250 shares of the Issuer's Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020.
Remarks
Chief Financial Officer and Executive Vice President of Corporate Development